RxDoctor Payments Data

Brian Naccari, MD

Internal Medicine · Metairie, LANPI 1306805601

Payments from drug & device makers

$13,738in general payments, 2019–2025

Across 481 payments — averaging $28.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Swedish Orphan Biovitrum AB$3K
  • Ironwood Pharmaceuticals, Inc$2K
  • Pfizer$1K
  • AstraZeneca$945
  • Kowa Research Institute, Inc.$924
  • Lilly USA, LLC$741
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$8,023100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,738 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$98,592
Medicare patients
439
Services billed
1,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide225$271,127
JardianceEmpagliflozin223$219,263
EliquisApixaban176$169,691
FarxigaDapagliflozin Propanediol148$120,289
OzempicSemaglutide56$68,505
JanuviaSitagliptin Phosphate57$61,040
XareltoRivaroxaban34$47,306
LinzessLinaclotide30$32,345
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$18,829
MyrbetriqMirabegron21$16,946
Atorvastatin Calcium1,787$14,730
Atrovent HfaIpratropium Bromide16$13,002
Irbesartan758$12,482
Repatha SureclickEvolocumab13$11,572
TrulicityDulaglutide11$10,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$741$281,544236 claims
Boehringer IngelheimJardiance$506$219,263223 claims
PfizerEliquis$1,320$169,691176 claims
AstraZenecaFarxiga, Brilinta$945$124,812159 claims
Novo NordiskOzempic$468$68,50556 claims
MerckJanuvia$245$61,04057 claims
Johnson & JohnsonXarelto$272$47,30634 claims
AbbVieLinzess, Synthroid$248$36,13297 claims
GSKTrelegy Ellipta, Breo Ellipta$387$28,26939 claims
Astellas Pharma US IncMyrbetriq$135$16,94621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →